**Clinical Trials with CDK4/6 Inhibitors in HR+/HER2- mBC**

|  |  |
| --- | --- |
| Resource | Address |
| Cristofanilli M, Turner NC, Bondarenko I, et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): Final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. *Lancet Oncol*. 2016;17:425-439. | [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(15)00613-0/fulltext](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045%2815%2900613-0/fulltext) |
| Cristofanilli M, Rugo HS, Im SA, et al. Overall survival (OS) with palbociclib (PAL) + fulvestrant (FUL) in women with hormone receptor–positive (HR+), human epidermal growth factor receptor 2–negative (HER2–) advanced breast cancer (ABC): Updated analyses from PALOMA-3. *J Clin Oncol.* 2021;39(15 suppl):1000. | <https://ascopubs.org/doi/abs/10.1200/JCO.2021.39.15_suppl.1000> |
| Di Leo A, Toi M, Sohn J, et al. 2360\_PR MONARCH 3: Abemaciclib as initial therapy for patients with HR+/HER2- advanced breast cancer. *Ann Oncol.* 2017;28(suppl 5):609. | [https://www.annalsofoncology.org/article/S0923-7534(20)39108-0/fulltext](https://www.annalsofoncology.org/article/S0923-7534%2820%2939108-0/fulltext) |
| Finn RS, Martin M, Rugo HS, et al. Palbociclib and letrozole in advanced breast cancer. *N Engl J Med.* 2016;375:1925-1936. | <https://www.nejm.org/doi/10.1056/NEJMoa1607303> |
| Goetz MP, Toi M, Campone M, et al. MONARCH 3: Abemaciclib as initial therapy for advanced breast cancer. *J Clin Oncol*. 2017;35:3638-3646. | <https://ascopubs.org/doi/10.1200/JCO.2017.75.6155> |
| Hortobagyi GN, Stemmer SM, Burris HA, et al*.* Ribociclib as first-line therapy for HR-positive, advanced breast cancer. *N Engl J Med*. 2016;375:1738-1748. | <https://www.nejm.org/doi/10.1056/NEJMoa1609709> |
| Hortobagyi GN, Stemmer SM, Burris HA, et al. Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer. *Ann Oncol.* 2018;29:1541-1547. | [https://www.annalsofoncology.org/article/S0923-7534(19)32105-2/fulltext](https://www.annalsofoncology.org/article/S0923-7534%2819%2932105-2/fulltext) |
| Johnston S, Martin M, Di Leo A, et al. MONARCH 3 final PFS: A randomized study of abemaciclib as initial therapy for advanced breast cancer. *NPJ Breast Cancer.* 2019;5:5. | <https://www.nature.com/articles/s41523-018-0097-z> |
| Loibl S, Turner NC, Ro J, et al. Palbociclib combined with fulvestrant in premenopausal women with advanced breast cancer and prior progression on endocrine therapy: PALOMA-3 Results. *Oncologist.* 2017;22:1028-1038. | <https://academic.oup.com/oncolo/article/22/9/1028/6444567> |
| O’Shaughnessy J, Petrakova K, Sonke GS, et al. Ribociclib plus letrozole versus letrozole alone in patients with de novo HR+, HER2- advanced breast cancer in the randomized MONALEESA-2 trial. *Breast Cancer Res Treat.* 2018;168:127-134. | <https://link.springer.com/article/10.1007/s10549-017-4518-8> |
| Rugo HS, Finn RS, Diéras V, et al. Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up. *Breast Cancer Res Treat.* 2019;174:719-729*.* | <https://link.springer.com/article/10.1007/s10549-018-05125-4> |
| Rugo HS, Finn RS, Gelmon K, et al. Progression-free survival outcome is independent of objective response in patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer treated with palbociclib plus letrozole compared with letrozole: Analysis from PALOMA-2. *Clin Breast Cancer.* 2020;20:e173-e180. | [https://www.clinical-breast-cancer.com/article/S1526-8209(19)30668-8/fulltext](https://www.clinical-breast-cancer.com/article/S1526-8209%2819%2930668-8/fulltext) |
| Slamon DJ, Neven P, Chia S, et al. Phase III randomized study of ribociclib and fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: MONALEESA-3. *J Clin Oncol*. 2018;36:2465-2472. | <https://ascopubs.org/doi/10.1200/JCO.2018.78.9909> |
| Slamon DJ, Neven P, Chia S, et al. Overall survival with ribociclib plus fulvestrant in advanced breast cancer. *N Engl J Med*. 2020;382:514-524. | <https://www.nejm.org/doi/10.1056/NEJMoa1911149> |
| Slamon DJ, Neven P, Chia SKL, et al. Updated overall survival (OS) results from the phase III MONALEESA-3 trial of postmenopausal patients (pts) with HR+/HER2- advanced breast cancer (ABC) treated with fulvestrant (FUL) ± ribociclib (RIB). *J Clin Oncol*. 2021;39(15 suppl):1001. | <https://ascopubs.org/doi/abs/10.1200/JCO.2021.39.15_suppl.1001> |
| Sledge GW Jr, Toi M, Neven P, et al. MONARCH 2: Abemaciclib in combination with fulvestrant in women with HR+/HER2- advanced breast cancer who had progressed while receiving endocrine therapy. *J Clin Oncol*. 2017;35:2875-2884. | <https://ascopubs.org/doi/10.1200/JCO.2017.73.7585> |
| Sledge GW Jr, Toi M, Neven P, et al. The effect of abemaciclib plus fulvestrant on overall survival in hormone receptor-positive, ERBB2-negative breast cancer that progressed on endocrine therapy-MONARCH 2: A randomized clinical trial. *JAMA Oncol*. 2020;6:116-124. | <https://jamanetwork.com/journals/jamaoncology/fullarticle/2752266> |
| Turner NC, Slamon DJ, Ro J, et al. Overall survival with palbociclib and fulvestrant in advanced breast cancer. *N Engl J Med*. 2018;379:1926-1936. | <https://www.nejm.org/doi/10.1056/NEJMoa1810527> |

**Real-World Studies with CDK4/6 Inhibitors**

|  |  |
| --- | --- |
| Resource | Address |
| Brufsky A, Liu X, Li B, McRoy L, Layman RM. Real-world tumor response of palbociclib plus letrozole versus letrozole for metastatic breast cancer in US clinical practice. *Target Oncol.* 2021;16:601-611. | <https://link.springer.com/article/10.1007/s11523-021-00826-1> |
| Cuyun Carter G, Sheffield KM, Gossai A, et al. Real-world treatment patterns and outcomes of abemaciclib for the treatment of HR+, HER2- metastatic breast cancer. *Curr Med Res Opin.* 2021;37:1179-1187. | <https://www.tandfonline.com/doi/full/10.1080/03007995.2021.1923468> |
| Harbeck N, Bartlett M, Spurden D, et al. CDK4/6 inhibitors in HR+/HER2- advanced/metastatic breast cancer: A systematic literature review of real-world evidence studies. *Future Oncol.* 2021;17:2107-2122. | <https://www.futuremedicine.com/doi/10.2217/fon-2020-1264> |
| Singer CF, Egle D, Greil R, et al. 172P REACHAUT: Real-world study of first-line (1L) ribociclib (RIB) + endocrine therapy (ET) in HR+, HER2- metastatic breast cancer (MBC). *Ann Oncol*. 2020;31(suppl 2):S77-S78. | <https://oncologypro.esmo.org/meeting-resources/esmo-breast-cancer-virtual-meeting-2020/reachaut-real-world-study-of-first-line-1l-ribociclib-rib-endocrine-therapy-et-in-hr-her2-metastatic-breast-cancer-mbc> |
| Taylor-Stokes G, Mitra D, Waller J, Gibson K, Milligan G, Iyer S. Treatment patterns and clinical outcomes among patients receiving palbociclib in combination with an aromatase inhibitor or fulvestrant for HR+/HER2-negative advanced/metastatic breast cancer in real-world settings in the US: Results from the IRIS study. *Breast.* 2019;43:22-27. | [https://www.thebreastonline.com/article/S0960-9776(18)30316-3/fulltext](https://www.thebreastonline.com/article/S0960-9776%2818%2930316-3/fulltext) |

**Managing Adverse Events and Improving Access to CDK4/6 Inhibitors**

|  |  |
| --- | --- |
| Resource | Address |
| Conley CC, McIntyre M, Pensak NA, et al. Barriers and facilitators to taking CDK4/6 inhibitors among patients with metastatic breast cancer: A qualitative study [published online ahead of print, 2022 Jan 7]. *Breast Cancer Res Treat.* 2022;10.1007/s10549-022-06518-2. | <https://link.springer.com/article/10.1007/s10549-022-06518-2> |
| Thill M, Schmidt M. Management of adverse events during cyclin-dependent kinase 4/6 (CDK4/6) inhibitor-based treatment in breast cancer. *Ther Adv Med Oncol.* 2018;10:1758835918793326. | <https://journals.sagepub.com/doi/10.1177/1758835918793326> |
| Wander SA, Mayer EL, Burstein HJ. Blocking the cycle: Cyclin-dependent kinase 4/6 inhibitors in metastatic, hormone receptor-positive breast cancer. *J Clin Oncol.* 2017;35:2866-2870. | <https://ascopubs.org/doi/10.1200/JCO.2017.73.9482> |

***ESR1* Mutations in Breast Cancer and Proposed Mechanisms of Resistance to CDK4/6 Inhibitors**

|  |  |
| --- | --- |
| Resource | Address |
| Bidard FC, Callens C, Dalenc F, et al. Prognostic impact of ESR1 mutations in ER+ HER2- MBC patients prior treated with first line AI and palbociclib: An exploratory analysis of the PADA-1 trial. *J Clin Oncol.* 2020;38(15 suppl):1010. | <https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.15_suppl.1010> |
| Chandarlapaty S, Chen D, He W, et al. Prevalence of *ESR1* mutations in cell-free DNA and outcomes in metastatic breast cancer: A secondary analysis of the BOLERO-2 clinical trial. *JAMA Oncol.* 2016;2:1310-1315. | <https://jamanetwork.com/journals/jamaoncology/fullarticle/2542919> |
| Fribbens C, O'Leary B, Kilburn L, et al. Plasma *ESR1* mutations and the treatment of estrogen receptor-positive advanced breast cancer. *J Clin Oncol.* 2016;34:2961-2968. | <https://ascopubs.org/doi/10.1200/JCO.2016.67.3061> |
| Hortobagyi GN, Stemmer SM, Burris HA, et al. Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer. *Ann Oncol.* 2018;29:1541-1547. | [https://www.annalsofoncology.org/article/S0923-7534(19)32105-2/fulltext](https://www.annalsofoncology.org/article/S0923-7534%2819%2932105-2/fulltext) |
| Lei JT, Gou X, Seker S, Ellis MJ. *ESR1* alterations and metastasis in estrogen receptor positive breast cancer. *J Cancer Metastasis Treat*. 2019;5:38. | <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6519472/> |
| Portman N, Alexandrou S, Carson E, Wang S, Lim E, Caldon CE. Overcoming CDK4/6 inhibitor resistance in ER-positive breast cancer. *Endocr Relat Cancer.* 2019;26:R15-R30. | <https://pubmed.ncbi.nlm.nih.gov/30389903/> |
| Spoerkle JM, Gendreau S, Walter K, et al. Heterogeneity and clinical significance of *ESR1* mutations in ER-positive metastatic breast cancer patients receiving fulvestrant. *Nat Commun.* 2016;7:11579. | <https://www.nature.com/articles/ncomms11579> |

**Patient Resources**

|  |  |
| --- | --- |
| Resource | Address |
| American Cancer Society (ACS). Breast Cancer. Accessed February 25, 2022. | <https://www.cancer.org/cancer/breast-cancer.html> |
| Cancer*Care*®. Breast Cancer. Accessed February 25, 2022. | <https://www.cancercare.org/diagnosis/breast_cancer> |
| American Cancer Society (ACS). Informed Consent. What Is Informed Consent? Last revised May 13, 2019. | <https://www.cancer.org/treatment/treatments-and-side-effects/planning-managing/informed-consent/what-is-informed-consent.html> |
| National Cancer Institute (NCI). Breast Cancer-Patient Version. Accessed February 25, 2022. | [www.cancer.gov/types/breast](https://www.cancer.gov/types/breast) |
| National Cancer Institute (NCI). Cancer Screening Overview (PDQ®)–Patient Version. Updated August 19, 2020. | <https://www.cancer.gov/about-cancer/screening/patient-screening-overview-pdq#_183> |